Clinical ACT trials with TCR transgenic T cells have so far evaluated the safety and anti-tumor function of T cells directed against differentiation antigens in melanoma (melanoma antigen recognized by T-cells 1, MART-1; tyrosinase/gp100) [81,82,83] and colorectal cancer (carcinoembryonic antigen, CEA) [84], CTAs (NY-ESO-1, MAGE) in a variety of solid tumors and multiple myeloma [4,5,6,7,77,79,85,86,87,88,89], the overexpressed self-antigen WT-1 in myeloid malignancies [9,90], and Human Papilloma Virus 16 (HPV-16)-associated antigen E6 in epithelial cancers [8]. The gene discussed is CEACAM5; the disease is AL amyloidosis.